drugset / Trial / NCT02658734

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

NCT02658734

Phase 4 Completed 70 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelBasic science

Summary

This is a Phase IV, single-arm, multicenter, open-label clinical trial designed to assess the safety of trastuzumab emtansine in Indian patients with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior treatment with trastuzumab and a taxane.

Timeline

Start
2016-11-01
Primary completion
2019-12-14
Completion
2019-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab emtansine Other / unclassified 3.6 mg/kg Intravenous